The Globe and Mail reports in its Tuesday edition that Martin Shkreli, the "pharma bro" who raised the price of a life-saving drug by 5,000 per cent, will go on trial on Monday for what U.S. prosecutors called a Ponzi-like scheme involving his former hedge fund. A Reuters dispatch to The Globe says that prosecutors have accused Mr. Shkreli of lying to investors in the hedge fund and siphoning millions of dollars in assets from biotech Retrophin Inc. to repay them. He has pleaded not guilty. Mr. Shkreli, 34, outraged patients and U.S. lawmakers by raising the price of anti-parisitic drug Daraprim to $750 (U.S.) a pill, from $13.50 (U.S.), in 2015, when he was chief executive officer of Turing Pharmaceuticals. The charges that led to his arrest in December, 2015, are not related to Turing but focus on Mr. Shkreli's management at Retrophin and the hedge fund MSMB Capital Management between 2009 and 2012. Prosecutors said that Mr. Shkreli lied about MSMB's finances to lure investors and concealed devastating trading losses from them. They said he paid the investors back with money stolen from Retrophin, which he founded in 2011. Despite the pending trial, Mr. Shkreli has continued to court the public eye.